Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022860 | 0.99 | LPAR1 (0.44) | LPAR1GABRA5 | |
| SCHEMBL4022155 | 0.80 | LPAR1 (0.47) | LPAR1 | |
| SCHEMBL4023164 | 0.77 | LPAR1 (0.39) | LPAR1GABRA5 | |
| SCHEMBL4027626 | 0.71 | LPAR1 (0.44) | LPAR1 | |
| SCHEMBL4022280 | 0.68 | LPAR1 (0.41) | LPAR1 | |
| SCHEMBL4025736 | 0.67 | PTPN1 (0.37) | LPAR1 | |
| SCHEMBL4027629 | 0.65 | LPAR1 (0.39) | LPAR1 | |
| SCHEMBL4023550 | 0.61 | PTPN1 (0.39) | LPAR1GABRA5 | |
| SCHEMBL4034499 | 0.57 | LPAR1 (0.48) | LPAR1 | |
| SCHEMBL2929499 | 0.55 | CDH1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO., INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20060194850-A1 | Novel azole compound | AJINOMOTO CO. INC (JP) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885GABRA5 422/4885 |
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885GABRA5 422/4885 |
| US-20060194850-A1 | Novel azole compound | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885GABRA5 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.